

# NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

## HEALTH TECHNOLOGY APPRAISAL PROGRAMME

### Equality impact assessment – Guidance development

#### **STA Brentuximab vedotin for treating relapsed or refractory systemic anaplastic large cell lymphoma [ID512]**

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme.

#### **Consultation**

- |   |
|---|
| 1. Have the potential equality issues identified during the scoping process been addressed by the committee, and, if so, how? |
|---|

No potential equality issues were identified during the scoping process.
--

- |  |
|--|
| 2. Have any other potential equality issues been raised in the submissions, expert statements or academic report, and, if so, how has the committee addressed these? |
|--|

No potential equality issues have been raised in any part of the appraisal process.
---

- |  |
|--|
| 3. Have any other potential equality issues been identified by the committee, and, if so, how has the committee addressed these? |
|--|

No potential equality issues have been raised by committee.
---

- |  |
|--|
| 4. Do the preliminary recommendations make it more difficult in practice for a specific group to access the technology compared with other |
|--|

groups? If so, what are the barriers to, or difficulties with, access for the specific group?
Not applicable

5. Is there potential for the preliminary recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?
Not applicable

6. Are there any recommendations or explanations that the committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 4 or 5, or otherwise fulfil NICE's obligations to promote equality?
Not applicable

7. Have the committee's considerations of equality issues been described in the appraisal consultation document, and, if so, where?
Not applicable

**Approved by Associate Director (name):** Frances Sutcliffe.....

**Date:** 07/06/2017

**Final appraisal determination**

(when an ACD issued)

1. Have any additional potential equality issues been raised during the consultation, and, if so, how has the committee addressed these?

None

2. If the recommendations have changed after consultation, are there any recommendations that make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group?

The clinical effectiveness evidence for brentuximab vedotin was obtained from patients who have an eastern cooperative oncology group (ECOG) performance status of 0 or 1 and therefore the recommendation reflects this. The committee concluded that healthcare professionals should take into account any physical, sensory or learning disabilities, or communication difficulties that could affect ECOG performance status and make any adjustments they consider appropriate.

3. If the recommendations have changed after consultation, is there potential for the recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?

No.

4. If the recommendations have changed after consultation, are there any recommendations or explanations that the committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 2 and 3, or otherwise fulfil NICE's obligations to promote equality?

Recommendation 1.2 says 'When using ECOG performance status, healthcare professionals should take into account any physical, sensory or

learning disabilities, or communication difficulties that could affect ECOG performance status and make any adjustments they consider appropriate.'

5. Have the committee's considerations of equality issues been described in the final appraisal determination, and, if so, where?

Section 3.30 of the Final Appraisal Determination

**Approved by Associate Director (name):** Frances Sutcliffe

**Date:** 16/08/2017